tbuckley/cabot-search huggingface dataset:
Études neurologiques.
Journal: JAMA (1923)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Quality of Medical Information on the Internet
Authors: John Mack
Journal: JAMA (1997)

<h3>To the Editor.</h3> —I applaud the recognition by<i>JAMA</i>of the problem facing patients and medical professionals alike when assessing the quality of medical information on the Internet (Net).<sup>1</sup>As a moderator of several e-mail medical discussion groups, I have firsthand knowledge of the good, the bad, and the ugly that is medical publishing on the Net. It is not always easy, even for professionals, to know what is credible medical information on the Net and what is not. Of course, physicians could access only the mainstream publications and government sites, but the information may not be fresh, considering the lengthy peer review and political processes that may be involved. After all, one of the main reasons to use the Internet is to find other sources of up-to-date information. For example, physicians might like to get independent reviews of presentations made at medical meetings the same day as the
Stones are crushed and many patients elated by results of new ESWL therapy
Authors: M. F. Goldsmith
Journal: JAMA (1986)

"LIKE A LOUD cap pistol... a staple gun... a rifle shot." Whatever the aural image, these descriptions echo the new sound of success for urologists vanquishing an age-old foe: kidney stones. The blasts—lasting a fraction of a second each but occurring up to 1800 times in the course of one usual treatment—are made by the Dornier Kidney Lithotripter, or "stone crusher," a device developed by the German aerospace corporation (and marketed by Dornier Medical Systems, Inc, Marietta, Ga) for disintegrating renal and upper ureteral calculi by means of acoustic shock waves (<i>JAMA</i>[MEDICAL NEWS] 1983;249:2434-2435). Seldom has a new medical therapy— not to speak of one requiring an outlay of nearly $2 million for equipment— gained so many satisfied adherents so fast. According to a report issued this May by the Congressional Office of Technology Assessment (OTA) (<i>Health Technology Case Study 36: Effects of Federal Policies in Extracorporeal Shock Wave</i>
Progress report of evaluation of methadone maintenance treatment program as of March 31, 1968
Journal: JAMA (1968)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2024 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Risks and benefits of phase I trials: Twelve-years experience from a single institution.
Authors: U. Swami, M. H. Ghalib, I. Chaudhary, J. Y. Hou, S. Aparo, M. H. Einstein, G. L. Goldberg, T. N. Elrafei, S. Gajavelli, B. Cohen, L. Rajdev, A. Kaubisch, M. Haigentz, S. Mani, S. Goel
Journal: Journal of Clinical Oncology (2011)

6098 Background: Phase I trials are a critical component of drug development; yet are considered non-therapeutic. This leads to recruitment barriers due to provider and patient discomfort. The largest meta-analysis of phase I studies has previously shown a response rate (RR) of 10.6%. Herein we report the results from our institution. Methods: Records of patients enrolled on phase I trials at our institution from January 1999 to December 2010 were reviewed. Recorded data included adverse events (AE); treatment related responses and deaths. Kaplan-Meier analysis and t-test were performed on the reviewed data. Results: During this period 602 patients were accrued on 41 phase I trials [56.1% cytotoxic, 31.7% biological, 9.8% both and 2.4% viral agents]. Primary cancer diagnoses included colorectal (25.5%), ovarian (19.1%), uterine (6.9%) and breast (6.9%). In total, 473 patients were evaluable for response, 40.3% had stable disease (SD) and overall RR was 8.6% (complete RR =1.27%). Patients with overall clinical benefit (SD+response) had lower mean baseline WBC (4.25 vs 5.4 k/uL, p<0.003), ANC (2.5 vs 3.8 k/uL, p<0.001), platelets (201 vs 232 k/uL, p<0.003), LDH (300 vs 372 U/L, p<0.017) and higher serum albumin (3.95 vs 3.84 g/dL, p<0.035) as compared to patients with progressive disease. Grade 3/4 non-hematological and hematological AE were seen in 38% and 20.5% patients, respectively. Treatment-related mortality was 1.2%. Patients with baseline LDH ≤200 U/L [upper limit of normal (UNL)] had a higher median survival (328 days vs 180 days, p<0.001, HR 0.48, 95% CI 0.375-0.616) as compared to LDH >300 U/L (1.5 X UNL). The median and mean duration on study were 51 and 83 days, respectively. Conclusions: This is one of the largest single-institution series of phase I oncology trials. Our RR of 8.6% [95% CI 6.3-11.6%] falls within the 95% CI of the RR of a majority of third line (and greater) chemotherapy regimens for solid tumors. Thus, the concept of 'non-therapeutic' nature of phase I studies needs reconsideration.
New Techniques Improve Efficiency of Peritoneal Dialysis
Journal: JAMA (1965)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
<i>Circulation</i> : Clinical Summaries
Journal: Circulation (2011)

A conventional approach to characterize the function of ion channel mutations is to compare wild-type and variant channel function by heterologous expression in mammalian, noncardiac cells like Chinese hamster ovary or human embryonic kidney cells.The cardiac sodium channel mutation D1275N has been reported in multiple individuals and families with a range of phenotypes, including arrhythmias and dilated cardiomyopathy; however, conventional heterologous expression studies have not identified major differences between wild-type and D1275N function.Thus, it has even been uncertain whether this mutation causes the clinical phenotypes with which it has been associated.In this study, we addressed this issue by studying mice in which the cardiac sodium channel locus had been disrupted and replaced with full-length human wild-type or D1275N mutant sodium channels.We observed slowed and disordered cardiac conduction and decreased contractile function in mice bearing the mutation; mice with 2 D1275N alleles displayed worse phenotypes than those with 1 variant allele.In vitro electrophysiological studies identified reduced peak cardiac sodium current as a key defect, and this is consistent with the observed reduced conduction velocity.The major clinical implication of these findings is that heterologous expression may be insufficient to assess mutant channel function.In addition, the data lend support to the concept that sodium channel mutations are associated not only with arrhythmias but also with dilated cardiomyopathy phenotypes.The mutant mice will be an invaluable tool to dissect mechanisms underlying these findings.See p 1001.
Pietro d'Abano of Padua (1250-1315) translator and scholiast
Journal: JAMA (1967)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Phase I clinical trial of a genetically modified and oncolytic vaccinia virus GL-ONC1 with green fluorescent protein imaging (NCT009794131).
Authors: Khurum Hayat Khan, Anna-Mary Young, Joaquin Mateo, Nina Tunariu, Timothy Anthony Yap, David Shao Peng Tan, David Mansfield, Mabel Wong, Ruth Riisnaes, Kevin J. Harrington, Johann Sebastian De Bono
Journal: Journal of Clinical Oncology (2013)

3062 Background: GL-ONC is a genetically engineered virus attenuated by insertion of the ruc-gfp (Renilla luciferase and Aequorea green fluorescent protein fusion gene), beta-galactosidase (lacZ) and beta-glucuronidase (gusA) reporter genes into the FL14.5L, J2R (thymidine kinase) and A56R (hemagglutinin) loci, respectively. A phase I trial of intravenous (i.v) GL-ONC1 was pursued to evaluate safety, tolerability, tumour delivery, neutralising antibody development and antitumor activity. Methods: GL-ONC1 was administered at escalating doses (1x10 5 , 1x10 6 , 1x10 7 , 1x10 8 , 1x10 9 , 3x10 9 plaque forming units (pfu) on day 1; 1.667x10 7 and 1.667x10 8 , 1.667x10 9 pfu on days 1-3) utilizing a 28-day cycle and a 3+3 dose escalation design. Paired biopsies before treatment and on day 8 for pharmacodynamic and viral delivery evaluation were obtained. Green flourescent protein (GFP) imaging was performed on skin rash and mucosal tumour lesions at baseline and after each cycle. Results: To date, 33 patients (pts) across 8 cohorts have been treated with 1 dose limiting toxicty reported of grade 3 transaminitis after a single infusion at 1x10 9 pfu. Other reported adverse events (n) included pyrexia (26), musculoskeletal pain (10), fatigue (8), nausea and vomiting (4). 2 pts had transient transaminitis; both had liver metastases, which may have contributed to this. 2 pts developed minimally symptomatic poxvirus skin pustules, which appeared green by GFP and were positive to viral plaque assay (VPA). Overall, stable disease (SD) by RECIST was seen at &gt;24 weeks (n=6) and 8-12 weeks (n=5). 2 out of 4 pts in cohort 8 (one with cholangiocarcinoma and another with non-small cell lung caner) achieved SD for median 5.5 months, with a drop in tumour markers at the time of infusions. Conclusions: GL-ONC1 is well tolerated; more frequent delivery of the virus (2 weekly, at the same dose) is planned in an attempt to increase agent exposure. Clinical trial information: NCT009794131.
JAMA Pediatrics
Authors: Phil Fontanarosa, Annette Flanagin, Brenda Gregoline, Tracy Frey, Shannon Sparenga, Nicole Balin, Miriam Cintron, Paul Ruich, Diane Cannon, Connie Manno, Fred Marshall, Laura Copyreaders, Catherine Adamczyk, Stephanie Alden, Jan Beckmeyer, Mary Clavey, Paula Coerver-Connolly, Roya Glitman, Laura Khatiblou, Donna King, Caroline Thordsen, Wanda Assistant, Larry Bryant, Monica Mungle, Elaine Williams, Lenette Gardner-Gullens, Fanny Brown, Paul Frank, Peter Kim, Rachell Lozano, Michaela Mark, Kathryn Muskovich, Gale Saulsberry, Michael Berkwits, Michelle Kurzynski, Eric Butkus, Will English, Christopher Hastings, Craig Mccaffrey, Reuben Rios, Ronna Henry, Joshua Bird, Karen Bucher, Samantha Welker, David Song, Deputy Livingston, Thomas Cole, Marla Hall, Deanna Willis, Yolanda Davis, Joseph Thornton, Preeti Malani, Deanna Bellandi, Jim Periodical, Thomas Easley Vice, Brian Shields, Monica Smith, Jeffery Bonistalli Manager, Kathy Russell, Mirna Monal, Tim Melroy, Marketing Thornbury, Tricia Castellano, Thalia Moss, Mike Harvey, Susan Henning, Saskia Bolore, Gretchen Linder, Brian Mccartney, David Baum, Rebecca Haas, Christine Hearne, Irma Lara, Ron Thomas, Paul Gee, Matt Herron, Elizabeth Solaro, Geoffrey Flick Managers, Rick Bell, Lindsay Dawson, Michael Mcgraw, Romando Rossini, Stacy Staff, Millette Jackson-Bates, Karen Adams-Taylor, Karl Elvin, Jaye Mize, Sean O'donnell, Sue Managers, David Antos, Chris Borden, Debbie Camp, Lydia Cruz, Scott Curl, Diane Darnell, Colleen Kelly, Chris Meyer, Annemarie Neff, J Neff, Sean Ohlson, Phil O'leary, Bill Pedone, Susan Price, Denise Steinhauser, Production Services, Kim Boler, Rhonda Brown, Timothy Burke, Daniel Degroot, Jordynn Farrar, Euwanaha Joiner-Smith, Tiffany Jones, Cindy Rendlen, Ellen Yoshihara, Circulation Services, Julie Burton, Dexter Golden, Erin Hinchcliff, Maria Nienhaus, Noemi Rivera, Geneine Van, Someren Composition, New Media, Gail Barrett, Regina Brownlee, Amanda Camino, Brenda Chandler-Grayer, Emily Dunn, Amy Evers, Teri Hutchison, Mary Kuranda, Joshua Lampinen, Nathan Mitre, Patricia Panek, La Son, Diggs Sledge, George Thomson Graphics, Joe Amft, Maria Duda, Fred Furtner, Carolyn Hall, Maria Kowalkowski, Proofreading Carol, Joy Farrell, Daniel James, Judith Literskis, Teresa Omiotek, Sam Wilder, James Madara, Bernard Hengesbaugh, Dimitri Christakis, Washington Joffe, Ron Keren, Debra Palazzi, Suzanne Shuey, Samir Shah, Howard Bauchner, Frederick Rivara, Joyce Lee, Ann Arbor, Jay Berry, Cherrie Boyer, San Francisco, Maria Britto, John Campo, Aaron Carroll, Indiana Frank, Joseph Chaloupka, Mitchell Cohen, Kathleen Janz, Iowa City, Terry Klassen, Michigan Michelle, Huckaby Lewis, Aaron Milstone, Shawn Rangel, Martha Sola-Visner
Journal: JAMA Pediatrics (2015)
The authors reply
Authors: H F. DOWNEY
Journal: Cardiovascular Research (1992)

Journal Article The authors reply Get access H FRED DOWNEY H FRED DOWNEY Department of Physiology, Texas College of Osteopathic Medicine, Fort Worth, Texas, USA Search for other works by this author on: Oxford Academic PubMed Google Scholar Cardiovascular Research, Volume 26, Issue 5, May 1992, Page 557, https://doi.org/10.1093/cvr/26.5.557 Published: 01 May 1992
Incorrect Version Published
Journal: JAMA (2016)

Navdeep Tangri, MD, PhD, FRCPC; Morgan E. Grams, MD, PhD; Andrew S. Levey, MD; Josef Coresh, MD, PhD; Lawrence J. Appel, MD; Brad C. Astor, PhD, MPH; Gabriel Chodick, PhD; Allan J. Collins, MD; Ognjenka Djurdjev, MSc; C. Raina Elley, MBCHB, PhD; Marie Evans, MD, PhD; Amit X. Garg, MD, PhD; Stein I. Hallan, MD, PhD; Lesley A. Inker, MD, MS; Sadayoshi Ito, MD, PhD; Sun Ha Jee, PhD; Csaba P. Kovesdy, MD; Florian Kronenberg, MD; Hiddo J. L. Heerspink, PharmD, PhD; Angharad Marks, MBBCh, MRCP, MSc, PhD; Girish N. Nadkarni, MD, MPH; Sankar D. Navaneethan, MD, MPH; Robert G. Nelson, MD, PhD; Stephanie Titze, MD, MSc; Mark J. Sarnak, MD, MS; Benedicte Stengel, MD, PhD; Mark Woodward, PhD; Kunitoshi Iseki, MD, PhD; for the CKD Prognosis Consortium
Drowning mortality in Los Angeles County, 1976 to 1984
Authors: P. W. O'Carroll
Journal: JAMA (1988)

Drowning is the fourth leading cause of unintentional injury death in Los Angeles County. We examined data collected by the Los Angeles County Coroner's Office on drownings that occurred in the county from 1976 through 1984. There were 1587 drownings (1130 males and 457 females) during this nine-year period, for an annual rate of 2.36 drownings per 100 000 persons (3.44 for males and 1.33 for females). The largest proportion of drownings (44.5%) for both sexes, and in almost every age group, occurred in private swimming pools. Children 2 to 3 years of age had the highest swimming-pool drowning rate (7.95). The elderly also experienced high drowning rates, primarily in swimming pools and bathtubs. Drowning-site profiles varied dramatically by age and sex. These findings indicate a need for Los Angeles County to address the problem of drownings among infants and toddlers in private swimming pools and to investigate the failure of regulations requiring fencing of swimming pools to prevent these deaths. These findings also suggest several potential opportunities for preventive intervention by physicians and demonstrate that health professionals cannot rely on national drowning-site profiles when developing local drowning prevention strategies. (<i>JAMA</i>1988;260:380-383)
Die Behandlung und Verhütung der Rachitis und Tetanie nebst Bemerkungen zu ihrer Pathogenese und Ätiologie.
Journal: JAMA (1930)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
PTSD Enzyme
Authors: Tracy Hampton
Journal: JAMA (2011)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Correlation
Authors: J. Fletcher
Journal: BMJ (2009)

<h3>Abstract</h3> Orthology assignment is a key step of comparative genomic studies, for which many bioinformatic tools have been developed. However, all gene clustering pipelines are based on the analysis of protein distances, which are subject to many artefacts. In this paper we introduce Broccoli, a user-friendly pipeline designed to infer, with high precision, orthologous groups and pairs of proteins using a phylogeny-based approach. Briefly, Broccoli performs ultra-fast phylogenetic analyses on most proteins and builds a network of orthologous relationships. Orthologous groups are then identified from the network using a parameter-free machine learning algorithm. Broccoli is also able to detect chimeric proteins resulting from gene-fusion events and to assign these proteins to the corresponding orthologous groups. Tested on two benchmark datasets, Broccoli outperforms current orthology pipelines. In addition, Broccoli is scalable, with runtimes similar to those of recent distance-based pipelines. Given its high level of performance and efficiency, this new pipeline represents a suitable choice for comparative genomic studies. Broccoli is freely available at https://github.com/rderelle/Broccoli.
Dysfunctional adaptive immunity in liver cirrhosis and acute-on-chronic liver failure is characterized by aberrant immune checkpoint expression and diminished cytokine secretion in T cells
Authors: Sabrina Rueschenbaum, Sandra Ciesek, Alexander Queck, Marek Widera, Katharina Maria Schwarzkopf, Bernhard Brüne, Christoph Welsch, Heiner Wedemeyer, Stefan Zeuzem, Andreas Weigert, Christian Lange
Journal: Journal of Hepatology (2020)